David M. Polen
Polen Capital Management
Polen Capital Management Alnylam Pharmaceuticals Inc stake
total: 588
Polen Capital Management ALNY trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2025 Q3
- Held for:
- 1 quarter
- Latest activity:
- 2025 Q4
According to 2026 Q2 report, Polen Capital Management doesn't hold any Alnylam Pharmaceuticals Inc (ALNY) shares. To date, the estimated cost basis is nearly $456 for "buy" trades and estimated average "sell" price is $456. Polen Capital Management first purchased ALNY in 2025 Q3, initially acquiring 693 shares. Since the initial investment in Alnylam Pharmaceuticals Inc (ALNY), Polen Capital Management has made 1 more transaction.
When did Polen Capital Management sell Alnylam Pharmaceuticals Inc (ALNY)?
Polen Capital Management sold off the entire Alnylam Pharmaceuticals Inc (ALNY) position in 2025 Q4.
When did Polen Capital Management buy Alnylam Pharmaceuticals Inc (ALNY)?
Polen Capital Management first invested in Alnylam Pharmaceuticals Inc (ALNY) in 2025 Q3 at the reported quarter-end price of $456.00 per share.
What's the cost basis of Polen Capital Management's ALNY stake?
The estimated cost basis for Alnylam Pharmaceuticals Inc (ALNY) stake is around $456.00 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $456.00
- Weighted AVG sell price:
- $456.00
Polen Capital Management's historical trades in Alnylam Pharmaceuticals Inc
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q4
|
0.00%
|
0
|
$456.00
|
|
-100% (-693)
|
-0%
|
|
2025 Q3
|
0.00%
|
693
|
$456.00
|
$316,008
|
new
|
+0%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.